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Abstract
Objectives To investigate whether there is evidence that an
increasing proportion of HIV infected patients is starting to
experience increases in viral load and decreases in CD4 cell
count that are consistent with exhaustion of available treatment
options.
Design Multicentre cohort study.
Setting Six large HIV treatment centres in southeast England.
Participants All individuals seen for care between 1 January
1996 and 31 December 2002.
Main outcome measures Exposure to individual antiretroviral
drugs and drug classes, CD4 count, plasma HIV RNA burden.
Results Information is available on 16 593 individuals (13 378
(80.6%) male patients, 10 340 (62.3%) infected via homosexual
or bisexual sex, 4426 (26.7%) infected via heterosexual sex,
median age 34 years). Overall, 10 207 of the 16 593 patients
(61.5%) have been exposed to any antiretroviral therapy. This
proportion increased from 41.2% of patients under follow up at
the end of 1996 to 71.3% of those under follow up in 2002. The
median CD4 count and HIV RNA burden of patients under
follow up in each year changed from 270 cells/mm3 and 4.34
log10 copies/ml in 1996 to 408 cells/mm
3 and 1.89 log10
copies/ml, respectively, in 2002. By 2002, 3060 (38%) of
patients who had ever been treated with antiretroviral therapy
had experienced all three main classes. Of these, around one
quarter had evidence of “viral load failure” with all these three
classes. Patients with three class failure were more likely to have
an HIV RNA burden > 2.7 log10 copies/ml and a CD4 count
< 200 cells/mm3.
Conclusions The proportion of individuals with HIV infection
in the United Kingdom who have been treated has increased
gradually over time. A substantial proportion of these patients
seem to be in danger of exhausting their options for
antiretroviral treatment. New drugs with low toxicity, which are
not associated with cross resistance to existing drugs, are
urgently needed for such patients.
Introduction
The widespread use of highly active antiretroviral therapy
(HAART) has had a big impact on the prognosis of HIV infected
individuals.1 2 Although most people starting HAART will expe-
rience good virological responses to treatment, imperfect adher-
ence, tolerability problems, inadequate drug concentrations, and
pre-existing or newly developed antiretroviral resistance may
mean that in some patients, virological responses on their first
treatment combination will fail within the first few years.3 Com-
pared with the initial treatment regimen, subsequent regimens
are progressively less likely to produce a durable virological
response.4 The possibility of cross resistance developing to other
drugs in the same class (nucleoside reverse transcriptase inhibi-
tors, protease inhibitors, or non-nucleoside reverse transcriptase
inhibitors) means that individuals who experience virological
failure while receiving drugs from one of these classes tend to be
at a higher risk of virological failure if they are subsequently
treated with other drugs from the same class. Although new
drugs are continually being developed, concern has therefore
arisen that patients will ultimately exhaust all currently available
options for treatment.
We describe levels of exposure to antiretroviral treatment
and assess, at a population level, the relations between exposure
to antiretroviral drugs and immunological and virological status
in a large multicentre cohort of HIV infected patients from the
United Kingdom. We investigate whether there is evidence that
an increasing proportion of HIV infected patients is starting to
experience increases in viral load and decreases in CD4 count,
consistent with exhaustion of available treatment options.
Methods
The UK Collaborative HIV Cohort (UK CHIC) is a collaboration
of some of the largest HIV centres in the UK. The development
and characteristics of the cohort have been described in detail
elsewhere.5
Selection of patients
The criteria for inclusion of an individual in the UK CHIC study
were that the patient was HIV positive, older than 16 years, and
had attended one of the centres for care at any time after 1 Janu-
ary 1996. To date, data from existing clinical databases from six
centres (Chelsea and Westminster NHS Trust, King’s College
Hospital, Mortimer Market Centre, St Mary’s Hospital, Royal
Free Hospital, and Brighton and Sussex University Hospitals, see
bmj.com) have been merged. Data on demographics, AIDS
events and deaths, antiretroviral treatment, and laboratory tests,
were provided in a standardised format, including all
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information from the time of diagnosis. The analyses presented
here are based on data collected over the period 2003-4.
Clinics provided data in a pseudo-anonymised form, using
Soundex codes derived from surnames. We identified patients
who had transferred between the centres in the study by match-
ing on the basis of Soundex code and date of birth, and their
records were linked.
Statistical methods
Patients were included in the cohort from 1 January 1996, their
first attendance at one of the centres, or their 16th birthday,
whichever occurred latest. We classified patients as under follow
up in each year if the dates when they were first and last seen at
any of the centres indicated that they were under follow up at
that centre in that year. We present data for 1996-2002.
We defined individuals as being exposed to an antiretroviral
drug if their treatment history included any use of that drug. We
reported use of the following antiretroviral drugs: nucleoside
reverse transcriptase inhibitors (zidovudine, lamivudine, stavu-
dine, didanosine, zalcitabine, lodenosine, and abacavir), protease
inhibitors (ritonavir, saquinavir (soft gel or hard gel formulation),
indinavir, nelfinavir, amprenavir, or lopinavir), non-nucleoside
reverse transcriptase inhibitors (efavirenz, nevirapine, delavird-
ine, and loviride), and a fusion inhibitor (enfuvirtide (T-20)). Use
of two nucleotide reverse transcriptase inhibitors, adefovir and
tenofovir, was limited over the study period; these drugs are
included as nucleoside reverse transcriptase inhibitors in this
analysis.
We used each patient’s last available CD4 count and plasma
HIV RNA burden in a year in the analysis of trends over time.We
included patients only if they were under follow up and had a
CD4 count or HIV RNA burden measured in that year. We did
not consider patients who were lost to follow up as treatment
failures.
We classified patients as having experienced virological
failure to a regimen containing a protease inhibitor if two
consecutive HIV RNA measurements had been above 500
copies/ml after at least six months’ exposure to protease inhibi-
tors. If patients had discontinued this class of drugs before the
second HIV RNA measurement above 500 copies/ml we did not
classify them as experiencing virological failure.We defined viro-
logical failure on a regimen that contained non-nucleoside
reverse transcriptase inhibitors in a similar manner: we then
classified patients as experiencing three class failure if they had
experienced failure with regimens containing both protease
inhibitors and non-nucleoside reverse transcriptase inhibitors
(we assumed that failure had occurred with nucleoside reverse
transcriptase inhibitors, as protease inhibitors or non-nucleoside
reverse transcriptase inhibitors were rarely used without
nucleoside reverse transcriptase inhibitors); we took the date of
experiencing three class failure as the later of the dates of failure
on a protease inhibitor and non-nucleoside reverse transcriptase
inhibitors containing regimen. We considered CD4 count and
HIV RNA trends separately in three groups: patients who had
ever received antiretroviral therapy, patients who had been
exposed to three or more classes of drugs, and patients who had
experienced three class failure. We used the statistical package
SAS, version 8, for all analyses.
Results
The database contains information on 16 593 individuals from
six centres.Most (n = 13 378; 80.6%) were male, the predominant
risk factor for HIV infection was homosexual or bisexual sex
(10 340; 62.3%), with 4426 (26.7%) reporting a heterosexual risk.
The median (interquartile range) age of the cohort at first study
visit was 34 (29-39) years. Fifty six per cent (n = 9201) of the
cohort were white, 2987 (18.0%) were of black African ethnicity,
and 2101 (12.7%) were of other ethnicities (information on eth-
nicity is unknown for 13.9%). More than a quarter (4336; 26.1%)
have developed AIDS, and 1255 (7.6%) have died.
The number of individuals under follow up in the cohort
rose each year, from 7588 in 1996 to 11 200 in 2002. Changes in
the number of individuals under follow up reflect the number of
individuals attending one of the clinics for the first time in the
year as well as the number of individuals who had previously
been seen but were not seen at any of the cohort centres in that
year. The proportions of cohort participants who were “new” to
the cohort in 1997, 1998, 1999, 2000, 2001, and 2002 were
18.9%, 16.3%, 14.0%, 13.6%, 14.8%, and 14.0%, respectively,
whereas the proportions who had been seen in the previous year
but were not seen in these years were 15.4%, 9.2%, 8.5%, 8.1%,
8.2%, and 8.9%, respectively.
Overall, 10 207 of the 16 593 patients (61.5%) had been
exposed to any antiretroviral therapy, 10 176 (61.3%) to
nucleoside reverse transcriptase inhibitors, 5657 (34.1%) to pro-
tease inhibitors, and 6857 (41.3%) to non-nucleoside reverse
transcriptase inhibitors. Only 450 (2.7%) patients had been
exposed to enfuvirtide. As expected, patterns of exposure
changed over time (table 1). By the end of 1996, 41.2% of
patients under follow up in that year had been exposed to
antiretroviral therapy (14.0% to protease inhibitors, 3.8% to non-
nucleoside reverse transcriptase inhibitors). The maximum
number of antiretroviral drugs to which each patient had been
exposed was nine. By the end of 2002 the proportions of patients
seen in that year who had been exposed to any antiretroviral
therapy, protease inhibitors, and non-nucleoside reverse
transcriptase inhibitors had risen to 71.3%, 40.7%, and 53.5%,
respectively, and patients had been exposed to a median of four
(range 0-16) different antiretroviral drugs.
Table 1 Exposure to different classes of antiretroviral drugs among individuals from the UK CHIC study
Year
No of
patients
under follow
up
Nucleoside reverse transcriptase
inhibitors Protease inhibitors
Non-nucleoside reverse
transcriptase inhibitors Any antiretroviral drug
No (%)
exposed
Median (range)
No of drugs
No (%)
exposed
Median
(range) No of
drugs No (%) exposed
Median
(range) No of
drugs No (%) exposed
Median
(range) No of
drugs
1996 7588 3086 (40.7) 0 (0-5) 1063 (14.0) 0 (0-3) 291 (3.8) 0 (0-2) 3130 (41.2) 0 (0-9)
1997 7918 4277 (54.0) 2 (0-6) 2656 (33.5) 0 (0-4) 910 (11.5) 0 (0-2) 4328 (54.7) 2 (0-11)
1998 8599 5231 (60.8) 2 (0-7) 3607 (42.0) 0 (0-4) 2040 (23.7) 0 (0-3) 5266 (61.2) 3 (0-14)
1999 9170 5992 (65.3) 2 (0-7) 3973 (43.3) 0 (0-5) 3363 (36.7) 0 (0-4) 6017 (65.6) 3 (0-14)
2000 9775 6643 (68.0) 2 (0-7) 4114 (42.1) 0 (0-6) 4461 (45.6) 0 (0-4) 6661 (68.1) 3 (0-16)
2001 10 549 7340 (69.6) 2 (0-7) 4312 (40.9) 0 (0-6) 5315 (50.4) 1 (0-4) 7356 (69.7) 3 (0-16)
2002 11 200 7973 (71.2) 2 (0-7) 4561 (40.7) 0 (0-6) 5986 (53.5) 1 (0-4) 7987 (71.3) 4 (0-16)
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The median CD4 count of patients under follow up in each
year rose steadily from 270 cells/mm3 in 1996 to 408 cells/mm3
in 2002; the proportion with a CD4 count < 200 cells/mm3 fell
from 38.0% to 13.3% over the same period (table 2). The median
HIV RNA burden fell from 4.34 log10 copies/ml in 1996 to 1.89
log10 copies/ml in 2002, and the proportion of patients with a
viral load > 2.7 log10 copies/ml fell from 92.0% to 40.6%.
Among patients who had ever received antiretroviral
treatment, the proportion with a CD4 count < 200 cells/mm3
fell from 57.1% in 1996 to 15.3% in 2002, whereas the
proportion with an HIV RNA measurement > 2.7 log10
copies/ml fell from 89.3% to 23.5% (table 3). The number of
patients exposed to all three main classes of drugs increased
from 1% of those under follow up in 1996 to 27.3% of those
under follow up in 2002. The proportions of these patients who
showed signs of therapeutic failure in each year were similar to
those seen in the overall treated population. Among patients
exposed to three drug classes, the proportion experiencing three
class failure increased until 2000 but remained relatively stable
thereafter. Among patients in this group, the proportions with a
CD4 count < 200 cells/mm3 or an HIV RNA measurement
> 2.7 log10 copies/ml were high but seemed to be falling over
time.
Discussion
Although patients infected with HIV in the United Kingdom are
becoming increasingly exposed to different antiretroviral
treatments over time, immunological and virological profiles of
these patients continue to improve at a population level.
However, a small number of these individuals seem to be in dan-
ger of exhaustion of future treatment options.
As expected, an increasing proportion of individuals with
HIV infection in the United Kingdom have been treated with
antiretroviral therapy over time and, in line with this, their viro-
logical and immunological status has improved. Currently little
evidence exists to indicate that a large proportion of patients are
starting to experience therapeutic failure; this proportion has
remained relatively stable since 2000. Even among patients who
had experienced therapeutic failure with regimens containing all
three classes of drugs, immunological and virological status has
improved. We believe that these findings reflect the increasing
number of new drugs that become available each year and the
growing emphasis that is now placed on achieving good adher-
ence, even in patients who have previously experienced
problems when taking these drugs. However, the immunological
and virological status of patients who have experienced three
class failure remains relatively poor, showing that for a small
number, treatment options are in danger of becoming
exhausted.
Several new drugs from existing and new classes have
recently been licensed.6–9 Other drugs in development may offer
hopes of activity against existing resistant strains, or benefits in
terms of reduced toxicity or a reduction in the number of pills
that must be taken.10 However, past experience shows that
preliminary reports of new drugs being associated with minimal
cross resistance to other drugs are often followed by less positive
findings.11 Whether the trends seen up to the end of 2002 in this
current dataset have continued since will therefore be interesting
to see.
Potential limitations
We have considered the impact of antiretroviral therapy on HIV
infected individuals in the United Kingdom at a population level.
Such trends should always be interpreted cautiously. In particu-
lar, increased CD4 counts over time may result from an increase
in the number of newly diagnosed individuals with high CD4
counts attending the centres in the collaboration. However,
results from the CD4 surveillance scheme in the United
Kingdom12 and from individual cohorts in the collaboration13 14
indicate that this is not the case. A second concern is that as this
is a dynamic cohort, patients may leave the cohort at any time as
Table 2 Overall trends in CD4 counts and HIV RNA levels over time among patients in the UK CHIC study
Year
No (%) of patients under follow
up with more than one CD4 cell
count in the year
Latest CD4 count (cells/mm3) in year No (%) of patients under follow
up with more than HIV RNA
measurement in the year
Latest HIV RNA (log10 copies/ml) in year
Median (interquartile
range) No (%) <200
Median (interquartile
range) No (%) >2.7
1996 5517 (72.7) 270 (120-447) 2094 (38.0) 2197 (29.0) 4.34 (3.51-4.97) 2022 (92.0)
1997 6188 (78.2) 310 (180-460) 1785 (28.9) 5830 (73.6) 3.55 (2.70-4.52) 4082 (70.0)
1998 6795 (79.0) 335 (206-490) 1594 (23.5) 6926 (80.5) 3.10 (2.54-4.27) 3907 (56.4)
1999 7588 (82.7) 369 (230-523) 1512 (19.9) 7680 (83.8) 2.65 (1.70-4.23) 3786 (49.3)
2000 8385 (85.8) 397 (260-570) 1340 (16.0) 8325 (85.2) 2.26 (1.70-4.19) 3761 (45.2)
2001 9545 (90.5) 404 (270-575) 1362 (14.3) 9506 (90.1) 1.90 (1.70-4.10) 4001 (42.1)
2002 10446 (93.3) 408 (275-583) 1393 (13.3) 10295 (91.9) 1.89 (1.70-4.11) 4180 (40.6)
Table 3 Trends in CD4 cell counts and HIV RNA levels over time among patients who had ever started antiretroviral therapy, patients with three class
exposure, and patients who had previously experienced three class failure
Year
Ever started antiretroviral treatment Exposure to three classes of drugs Treatment failure with three classes of drugs
No (% of
patients under
follow up)
CD4 counts
<200
cells/mm3
HIV RNA
measurements >2.7
log10 copies/ml
No (% of
patients who
ever received
antiretroviral
therapy)
CD4 counts
<200
cells/mm3
HIV RNA
measurements >2.7
log10 copies/ml
No (% of
patients
exposed to
three classes)
CD4 counts
<200
cells/mm3
HIV RNA
measurements >2.7
log10 copies/ml
1996 3130 (41.2) 1589 (57.1) 1272 (89.3) 72 (2.3) 50 (70.4) 36 (80.0) 0 — —
1997 4328 (54.7) 1517 (38.4) 2361 (60.5) 399 (9.2) 181 (47.6) 236 (61.9) 13 (3.3) 6 (46.2) 13 (100.0)
1998 5266 (61.2) 1382 (29.1) 2017 (41.7) 1159 (22.0) 423 (38.1) 466 (41.7) 117 (10.1) 68 (58.1) 101 (86.3)
1999 6017 (65.6) 1327 (23.9) 1913 (34.1) 1905 (31.7) 582 (31.6) 639 (34.5) 273 (14.3) 153 (56.9) 211 (77.9)
2000 6661 (68.1) 1172 (18.9) 1772 (28.8) 2413 (36.2) 508 (22.0) 638 (27.8) 371 (15.4) 164 (45.6) 224 (62.0)
2001 7356 (69.7) 1186 (16.8) 1730 (24.6) 2748 (37.4) 502 (18.7) 597 (22.3) 435 (15.8) 147 (34.4) 218 (50.9)
2002 7987 (71.3) 1182 (15.3) 1802 (23.5) 3060 (38.3) 502 (16.8) 693 (23.3) 467 (15.3) 150 (32.5) 210 (45.7)
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they move to centres that are not part of the collaboration. CD4
counts and HIV RNA values cannot be included in our analyses
once patients leave the cohort, which may be a source of bias,
particularly if those who were starting to experience therapeutic
failure were more likely to drop out of the cohort. Although it is
certainly true that some patients will have dropped out with
therapeutic failure, many will have dropped out for unrelated
reasons. The median last available CD4 count and HIV RNA
measurement for those who dropped out of the cohort was
above 200 cells/mm3 in 41% and < 2.7 log10 copies/ml in 32%,
respectively, implying that many of these patients did not have
therapeutic failure at their last visit. These proportions have
remained relatively stable over time; we therefore do not believe
that this will affect the trends seen.
One of the benefits of using data from a large multicentre
study is that it is more representative of the UK epidemic than
cohorts from single centres. However, although the dataset
currently includes data on a third of all HIV infected individuals
seen for care in the United Kingdom15 and patients in the cohort
are broadly representative of HIV infected individuals in the
UK,5 the cohort includes disproportionately more homosexual
men and individuals of white ethnicity than are seen in the
United Kingdom as a whole. Furthermore, as all centres actively
participate in research studies (including clinical trials of new
drugs), it is possible that exposure to novel treatments in these
clinics may occur sooner than in other centres. Finally,
discrepancies may still occur in histories of antiretroviral
treatment if patients attend other centres either before or during
the periods of follow up and treatment information from previ-
ous centres is incomplete. In this situation, our estimates of
exposure to antiretroviral therapy may be underestimated.
Meaning of the study
We have identified two groups thought to be at high risk of treat-
ment exhaustion: patients exposed to three or more drug classes
and those who had experienced virological failure on regimens
including both protease inhibitors and non-nucleoside reverse
transcriptase inhibitors. Not all treatment switches are made as a
result of virological failure; individuals may also change
treatments for convenience or to reduce toxicity. Thus, patients
who have been exposed to three classes of drugs may not have
experienced virological failure while receiving these drugs and
may not necessarily show signs of treatment exhaustion. Patients
who are known to have experienced virological failure while
receiving these drugs, however, would be expected to have devel-
oped some resistance to their failing regimens, possibly leading
to cross resistance to other drugs in the same class16 and placing
these individuals at high risk of therapeutic failure. Although this
group had higher HIV RNA measurements and lower CD4
counts than other treated individuals, virological failure is an
imperfect surrogate for the presence of resistance mutations, and
some of these patients may not have developed resistance to
both protease inhibitors and non-nucleoside reverse tran-
scriptase inhibitors. Close links with the UK HIV Drug
Resistance Database17 will allow us to deal with this question
directly once the use of resistance testing has become routine in
this group. Further follow up of clinical events in these patients
will allow us to assess whether our definition of three class failure
is a good indicator of subsequent poorer clinical outcome.
Our findings show that new drugs with low toxicity, which are
not associated with cross resistance to existing drugs, will be
needed for such patients.
The authors thank all the clinicians, data managers, and research nurses in
participating clinical centres (see bmj.com) who have helped with the provi-
sion of data for this project.
Contributors: CAS contributed to the initial concept and design of the
study, analysed and interpreted the data, and wrote the manuscript. She is
guarantor. TH and RM provided the central coordination for the study,
merged the datasets, and were involved with cleaning the datasets. FL pro-
vided input to the creation of datasets. ANP, RG, MAJ, MF, GS, PE, and BG
contributed to the initial concept and design of the study, supervised the
data collection, and provided input into the preparation of the manuscript.
SB and MSY provided input into the preparation of the manuscript. All
authors provided comments on the interpretation of the data and gave
approval for the final version to be submitted for publication.
Funding: Medical Research Council, UK (grant G0000199).
Competing interest statement: Many of the authors have over the previous
five years received reimbursement for attending symposiums, fees for
speaking, membership of advisory boards, organising education or consul-
tancy or funding for research from: Abbott (MY, SB, ANP, MAJ, RG, MF,
GS), Boehringer Ingelheim (CAS, MY, ANP, MF, GS), Bristol Myers Squibb
(BG, MY, SB, ANP, MAJ, MF, GS), Gilead Sciences (CAS, BG, MY, SB, ANP,
RG,MF, GS), GlaxoSmithKline (CAS, FL, BG, SB, ANP,MF), Pfizer Pharma-
ceuticals (BG, MF), Roche (MY, SB, MAJ, RG, MF), Schering Plough (RG)
and Tibotec (ANP). None of the authors hold any shares in any of the com-
panies.
Ethical approval: Multicentre research ethics committee and local ethics
committees.
1 Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declin-
ing morbidity and mortality among patients with advanced human immunodeficiency
virus infection. N Engl J Med 1998;338:853-860.
2 Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F,Mulcahy F, et al. AIDS across
Europe, 1994-98: the EuroSIDA study. Lancet 2000;356:291-296.
3 Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, et al. Human immu-
nodeficiency virus rebound after suppression to < 400 copies/mL during initial highly
active antiretroviral therapy regimens, according to prior nucleoside experience and
duration of suppression. J Infect Dis 2002;186:1086-91.
4 Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, et al. The use of and
response to second-line protease inhibitor regimens: results from the EuroSIDA study.
AIDS 2001;15:201-209.
5 The UK Collaborative HIV Cohort Steering Committee. The creation of a large
UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV
Cohort (UK CHIC) study. HIV Med 2004;5:115-24.
6 Lalezari J et al. Forty-eight week analysis of patients receiving T-20 as a component of
multi-drug salvage therapy. 13th International Conference on AIDS, abstract LBP116,
Durban, 9-14 July 2000.
7 Squires K et al. Atazanavir (ATV) qd and efavirenz (EFV) qd with fixed-dose ZDV+3TC:
comparison of antiviral efficacy and safety through wk 24 (AI424-034). 42nd
Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego,
abstract H-1076, 2002.
8 Colonno R, Rose R, Cianci C, Aldrovandi G, Parkin N, Friborg J. Emergence of
atazanavir resistance and maintenance of susceptibility to other PIs is associated with
an I50L substitution in HIV protease. Tenth Conference on Retroviruses and Oppor-
tunistic Infections, Boston, abstract 597, 2003.
What is already known on this topic
Highly active antiretroviral therapy (HAART) has had a
dramatic impact on the health of individuals infected with
HIV
For several reasons, however, many patients may not be able
to tolerate their initial treatment regimen or may
experience virological failure while receiving HAART
It may therefore be necessary to switch treatments on one
or more occasions, raising the concern that some patients
may exhaust all currently available treatment options
What this study adds
The immunological and virological status of infected
patients generally improved
A small but growing proportion of these patients, however,
seem to be in danger of exhaustion of current treatment
options
Papers
page 4 of 5 BMJ Online First bmj.com
9 Staszewski S, Gallant JE, Pozniak AL, Suleiman JMAH, DeJesus E, Lu B, Sayre J, et al.
Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combi-
nation with lamivudine and efavirenz in antiretroviral naïve patients: 96-week prelimi-
nary interim results. Tenth Conference on Retroviruses and Opportunistic Infections,
Boston, abstract 564b, 2003.
10 Gulick RM, Staszewski S. New drugs for HIV therapy. AIDS (2002);16(suppl
4):S135-S144.
11 Paulsen D, Liao Q, Fusco G, St. Clair M, Shaefer M, Ross L. Genotypic and phenotypic
cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-
experienced patients with HIV infection. AIDS Res Hum Retrovir 2002;18:1011-9.
12 Chadborn T, Dingley S,Morgan D, Evans BG. CD4 cell counts in HIV-infected adults at
HIV diagnosis in England and Wales, 1990 to 2001. Abstract O28. Presented at 9th
Annual Conference of the British HIV Association (BHIVA), Manchester, England,
24-26 April 2003.
13 Easterbrook PJ, Yu LM, Goetghebeur E, Boag F, McLean K, Gazzard B. Ten-year trends
in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic. AIDS
2000;14:561-71.
14 Barry SM, Lloyd-Owen SJ, Madge SJ, Cozzi-Lepri A, Evans AJ, Phillips AN, et al. The
changing demographics of new HIV diagnoses at a London centre from 1994 to 2000.
HIV Med 2002;3:129-34.
15 Public Health Laboratory Service Communicable Disease Surveillance Centre,
Institute of Child Health (London), Scottish Centre for Infection and Environmental
Health. HIV and AIDS in the UK in 2001. London: Communicable Duisease
Surveillance Centre, 2002.
16 Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Pat Care
STDs 2004;18:259-73.
17 The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group.
Long term probability of detection of HIV-1 drug resistance after starting antiretrovi-
ral therapy in routine clinical practice. AIDS (in press).
(Accepted 14 January 2005)
doi 10.1136/bmj.38369.669850.8F
Department of Primary Care and Population Sciences, Royal Free and UC Medical
School, London NW3 2PF
Caroline A Sabin professor of medical statistics and epidemiology
Teresa Hill database manager, UK CHIC study
Fiona Lampe lecturer in epidemiology and medical statistics
Andrew N Phillips professor of epidemiology
MRC Clinical Trials Unit, London NW1 2DA
Ryanne Matthias database programmer, UK CHIC study
Royal Free Centre for HIV Medicine, Royal Free Hospital, London NW3 2QG
Sanjay Bhagani consultant in HIV medicine
Mike S Youle director of HIV clinical research
Margaret A Johnson clinical director, HIV/AIDS
Centre for Sexual Health and HIV Research, Royal Free and UC Medical School,
Mortimer Market Centre, London WC1E 6AU
Richard Gilson senior clinical lecturer
Lawson Unit, Department of HIV Medicine, Brighton and Sussex University
Hospital Trust, Eastern Road, Brighton, BN2 5BE
Martin Fisher consultant physician in HIV/AIDS
Department of GU Medicine and Communicable Diseases, St Mary’s NHS Trust,
London W2
George Scullard consultant, HIV/GUM
Guy’s, King’s and St Thomas’ School of Medicine, London SE5 9RT
Philippa Easterbrook professor of HIV medicine
Kobler Centre, Chelsea and Westminster Hospital, London SW10 9NH
Brian Gazzard professor of HIV medicine
Correspondence to: C A Sabin c.sabin@pcps.ucl.ac.uk
Papers
BMJ Online First bmj.com page 5 of 5
